ArticlePsychiatry and clinical psychopharmacology2023
Use of Clonidine in Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder Comorbidity: Report of 3 Cases.
Article in Psychiatry and clinical psychopharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clonidine has been widely used in child and adolescent psychiatry, especially in attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD), which are recently categorized under neurodevelopmental disorders. However, it is not recommended as a first-line medication for treatment, and current data on the use of clonidine are limited. Herein, we present 3 cases with ADHD and ASD comorbidity, if any, as well as other neurodevelopmental disorders, including intellectual disability and Tourette's disorder, treated with clonidine. At the second-month follow-up, substantial improvements were observed in subscale scores of Conners's Parent Rating Scale-Revised Long Form, and Autism Behavior Checklist. Our case report indicated that clonidine is well tolerated, safe, and effective in improving both ADHD- and ASD-related symptoms as well as disruptive, aggressive behaviors and tics in children with multiple neurodevelopmental disorders.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.